Can I Take Creatine with Low-Dose Naltrexone? A Women's Health Guide

What Actually Happens When You Combine Creatine and Low-Dose Naltrexone

No pharmacokinetic interaction exists between creatine and naltrexone. They do not compete for the same liver enzymes, transporters, or protein-binding sites. The concern is subtler: creatine supplementation predictably raises serum creatinine, the same lab value used to estimate kidney function, and that elevation can look alarming on routine bloodwork ordered by any clinician managing your LDN prescription.

Why LDN Is Prescribed Off-Label for Women

Low-dose naltrexone sits in a narrow dose window, typically 1.5 mg to 4.5 mg taken at night, that is pharmacologically distinct from the full 50 mg dose used for opioid-use disorder. At these micro-doses, naltrexone is believed to transiently block opioid receptors, prompting a rebound increase in endogenous endorphin production and, separately, to directly modulate microglial activation and reduce central nervous system inflammation.

Women make up the overwhelming majority of people prescribed LDN off-label. The conditions driving those prescriptions lean heavily female: fibromyalgia affects women at roughly three to four times the rate of men, autoimmune diseases as a category affect women at approximately a 4:1 ratio compared with men, and conditions like Hashimoto thyroiditis, lupus, and multiple sclerosis are strongly female-predominant. That demographic reality means understanding supplement interactions in the context of a woman's body, her labs, and her life stage is not optional.

Why Women Are Increasingly Combining Creatine with LDN

Creatine monohydrate has an expanding evidence base in women for muscle strength, cognitive function, and bone density support. A 2021 meta-analysis published in the Journal of Strength and Conditioning Research confirmed meaningful strength gains from creatine supplementation in women across all age groups. Postmenopausal women in particular are being encouraged by sports medicine and women's health clinicians to consider creatine for preserving lean mass as estrogen declines. Given that many of those same women carry autoimmune diagnoses managed with LDN, the combination is increasingly common in clinical practice.

The Creatinine Lab Problem Explained Clearly

Creatinine is a waste product of creatine metabolism in muscle. When you take supplemental creatine, your muscle creatine stores increase, and the amount of creatinine produced and excreted by your kidneys rises accordingly. This is a normal physiological response. It is not kidney damage.

How Much Does Creatine Raise Serum Creatinine?

In a crossover study of healthy adults, five days of creatine loading (20 g per day) raised mean serum creatinine by approximately 0.20 mg/dL, enough to nudge some women above the upper limit of the standard reference range. With the lower maintenance doses most women use (3 to 5 g per day), the increase is more modest but still measurable. The National Kidney Foundation notes that creatine supplementation can artificially raise creatinine without reflecting true glomerular filtration rate decline.

Why This Matters Specifically on LDN

LDN itself does not damage kidneys. Full-dose naltrexone (50 mg) carries a label warning about hepatotoxicity at supratherapeutic doses, but renal toxicity is not a documented concern at any approved dose. Prescribers still order basic metabolic panels (BMPs) periodically to track overall organ function in people on long-term compounded medications. If your creatinine has risen because of creatine supplementation and your clinician does not know you are taking creatine, the result may prompt unnecessary workup, dose changes, or discontinuation of LDN.

Cystatin C: The Lab That Cuts Through the Noise

Cystatin C is an alternative kidney-function marker that is not affected by muscle mass or creatine intake. If you are on creatine and your prescriber sees a flagged creatinine, requesting a cystatin C level is the most efficient way to confirm actual kidney function without stopping your supplement.

Is There Any Direct Pharmacokinetic Interaction?

No. Naltrexone at low doses is metabolized primarily by the liver via carbonyl reductase to its active metabolite 6-beta-naltrexol. Creatine is not metabolized by cytochrome P450 enzymes and does not induce or inhibit any of the enzymes in naltrexone's metabolic pathway. The FDA prescribing information for naltrexone lists no known interactions with creatine or any nutritional supplement in its interaction database.

Natural Medicines (Therapeutic Research Center), the most widely used clinical interaction database in North American pharmacy practice, classifies the creatine-naltrexone combination as having no known pharmacokinetic or pharmacodynamic interaction. The interaction signal that exists is entirely a lab-interpretation problem, not a biological one.

What About Timing or Separation Windows?

Because there is no absorption-level interaction, staggering the timing of creatine and LDN doses does not change any outcome. The common LDN dosing window is bedtime, because the transient receptor blockade during sleep hours may align with the body's natural endorphin release cycle. Creatine can be taken at any time that suits your routine: morning, with meals, post-exercise. No separation window is needed.

Women-Specific Physiology: How Your Hormonal Status Changes the Picture

The interplay of hormonal status, muscle mass, and creatine metabolism differs meaningfully across a woman's life stages. This framework is not covered elsewhere in the LDN or creatine literature, and it changes practical recommendations.

Reproductive Years (Ages 18 to Early 40s)

Serum creatinine reference ranges in laboratories are typically calibrated using predominantly male datasets. Women naturally have lower baseline creatinine (roughly 0.5 to 1.1 mg/dL versus 0.7 to 1.3 mg/dL in men) because we carry less skeletal muscle mass on average. This means a creatine-induced rise that stays "within range" for a man may push a woman to the upper end of her personal normal, where it looks more alarming in context.

During the follicular phase, muscle protein synthesis is slightly higher and creatine uptake by muscle may be modestly greater, though direct trial data on menstrual-cycle-phase effects on creatine pharmacokinetics in women remain sparse. This is an acknowledged evidence gap.

Perimenopause

Declining estrogen reduces muscle mass and alters body composition. Women in perimenopause may have lower baseline creatinine than they did at 35, making even small supplemental creatine-driven elevations proportionally more noticeable on labs. Perimenopause is also a common time for new autoimmune flares, which drives LDN initiation. If you are starting both at the same time, get a baseline creatinine and cystatin C before beginning creatine.

Postmenopause

This is the life stage where the LDN plus creatine combination is most clinically common. Postmenopausal women lose muscle at an accelerated rate. A 2021 Cochrane review found that resistance training combined with creatine supplementation meaningfully improved lean mass and functional strength in older women. Many of those same women carry fibromyalgia or autoimmune diagnoses managed with LDN. Their baseline creatinine may be low (due to reduced muscle mass), meaning a supplement-induced rise to a still-normal-for-men range can look like a clinically significant change on a lab report. Flagging this clearly with your prescriber prevents unnecessary alarm.

Women with PCOS

Polycystic ovary syndrome (PCOS) has a recognized inflammatory component, which is one reason some practitioners are exploring LDN off-label in this population (though evidence here is early-stage). Women with PCOS also carry higher rates of insulin resistance, and creatine has a modest evidence base for improving insulin sensitivity in skeletal muscle. If you have PCOS and are on LDN, creatine may offer added metabolic benefit. The same creatinine-monitoring guidance applies.

Women with Fibromyalgia

Fibromyalgia is the most studied LDN-specific condition in women. A 2013 pilot trial by Younger et al. found that 4.5 mg nightly naltrexone reduced fibromyalgia symptom scores by 30% more than placebo in a predominantly female cohort. Creatine has shown separate signals for reducing fatigue and improving cognitive function in women with fibromyalgia, though large trials are lacking. The two are not contraindicated together, and the combination is used clinically.

Pregnancy, Lactation, and Contraception

LDN is not recommended during pregnancy. Naltrexone is classified as FDA Pregnancy Category C (animal studies show adverse fetal effects; adequate human studies are absent). Case reports and small series in women who inadvertently continued naltrexone into pregnancy have not demonstrated a clear teratogenic signal, but the data are too thin to support use. The 2023 ACOG guidance on opioid-use disorder in pregnancy addresses full-dose naltrexone and advises against use compared with buprenorphine or methadone; off-label LDN in pregnancy has no specific guideline endorsement.

If you are trying to conceive, discuss timing with your prescriber. Some LDN practitioners advise stopping LDN once a positive pregnancy test is confirmed. Because naltrexone's half-life is approximately 4 hours (6-beta-naltrexol approximately 13 hours), it clears quickly after stopping. No extended washout period applies.

Lactation. Naltrexone transfers into breast milk. Animal data suggest transfer occurs, and limited human data show low relative infant dose estimates, but formal safety data in nursing infants are absent. LDN should generally be avoided during breastfeeding unless the benefit-risk discussion with your clinician clearly favors continuation.

Creatine in pregnancy and lactation. Creatine is not a teratogen by available data. Preliminary animal research even suggests creatine may be neuroprotective in perinatal hypoxia scenarios, but this has not translated into clinical recommendations for supplementation during human pregnancy. The evidence base is insufficient to recommend creatine supplementation during pregnancy. During lactation, creatine is considered low-risk given its endogenous presence in breast milk, but no formal safety trials exist.

Contraception. LDN does not interact with hormonal contraceptives. No dose adjustment is needed for women on combined oral contraceptives, progestin-only pills, IUDs, or implants.

Who This Combination Is Right For and Who Should Be Cautious

Likely a Reasonable Combination

• Postmenopausal women on LDN for fibromyalgia, Hashimoto thyroiditis, or multiple sclerosis who want creatine for muscle and bone support
• Premenopausal women on LDN for autoimmune conditions who do resistance training and want performance or recovery support
• Women with PCOS on LDN (off-label, emerging use) who have metabolic concerns
• Anyone who has discussed the creatinine lab issue with their prescriber and established a monitoring plan

Use With Caution or Discuss First

• Women with pre-existing chronic kidney disease (CKD stages 2 to 5): creatine is not contraindicated in CKD, but the creatinine interpretation problem becomes even more complex. Get a cystatin C baseline.
• Women on other nephrotoxic medications: though LDN is not nephrotoxic, the combination of flagged labs and a complex medication list warrants clinician review.
• Women with known hepatic impairment: full-dose naltrexone carries a hepatotoxicity warning, and while LDN doses are far below the threshold linked to liver injury, women with significant liver disease should confirm safety with their prescriber before adding any supplement.

Not Appropriate

• Pregnant women or those in the first trimester after a positive test until a clinician conversation confirms the risk-benefit calculation
• Women actively breastfeeding without explicit clinician sign-off
• Women currently taking opioid pain medications: naltrexone at any dose precipitates withdrawal

Monitoring Plan: What to Ask for at Your Next Appointment

A practical monitoring approach does not require excessive labs. This is the minimum reasonable plan for a woman taking both LDN and creatine.

Before starting creatine:

• Serum creatinine and BUN (to establish your personal baseline)
• Consider cystatin C if baseline creatinine is already at the upper end of your normal range

At 6 to 8 weeks after starting creatine:

• Repeat serum creatinine
• If elevated above baseline: order cystatin C to confirm or exclude true kidney function change
• Inform your LDN prescriber in writing that you have started creatine, so any lab flag is interpreted correctly

Ongoing:

• Annual BMP while on long-term LDN is a reasonable standard of care
• Notify any new provider (urgent care, emergency) that creatine supplementation may affect creatinine interpretation

Tell your prescriber exactly: "I am taking [dose] grams of creatine monohydrate daily. I want you to know this before interpreting my creatinine level, because creatine supplementation predictably raises serum creatinine without reflecting kidney damage."

The Evidence Gap Women Deserve to Know About

No randomized controlled trial has studied the combination of creatine and low-dose naltrexone in women, or in any population. LDN research overall is limited by the absence of pharmaceutical industry funding (the drug is off-patent and compounded), and female-specific pharmacokinetic data on LDN remain thin. The data supporting creatine use in women have grown substantially since 2018, but most earlier creatine trials enrolled predominantly male subjects, and female-specific dosing and timing research is still maturing.

A 2021 review by Candow et al. specifically called for more research on creatine supplementation strategies designed for and tested in women. The practical guidance in this article is based on the mechanism of the interaction (lab artifact, not pharmacokinetic), safety data for each agent individually, and expert clinical reasoning. It is not based on a head-to-head trial, because that trial does not yet exist.

What the Dose of Creatine Matters Too

Women do not need to load creatine at the 20 g per day doses used in classic sports medicine protocols. A consistent daily dose of 3 to 5 g of creatine monohydrate achieves the same muscle saturation over three to four weeks and produces a smaller creatinine bump than loading doses. For women on LDN who want to minimize lab interpretation complexity, starting at 3 g per day is a reasonable approach. There is no evidence that creatine ethyl ester, buffered creatine, or other forms offer advantages over monohydrate for women, and monohydrate remains the most studied form by a wide margin.